AngioDynamics Inc. (ANGO)
Company Description
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors.
It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits.
In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency.
Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names.
It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships.
The company was founded in 1988 and is headquartered in Latham, New York.

Country | United States |
IPO Date | Jun 1, 2004 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 748 |
CEO | James C. Clemmer |
Contact Details
Address: 14 Plaza Drive Latham, New York United States | |
Website | https://www.angiodynamics.com |
Stock Details
Ticker Symbol | ANGO |
Exchange | NASDAQ |
Fiscal Year | June - May |
Reporting Currency | USD |
CIK Code | 0001275187 |
CUSIP Number | 03475V101 |
ISIN Number | US03475V1017 |
Employer ID | 11-3146460 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
James C. Clemmer | Chief Executive Officer, President & Director |
Stephen A. Trowbridge | Executive Vice President & Chief Financial Officer |
Benjamin H. Davis | Senior Vice President of Business Development & Strategy |
Chad T. Campbell | Senior Vice President & GM of Oncology and Interventional Devices |
Juan Carlos Serna | Senior Vice President of Scientific & Clinical Affairs |
Kim L. Seabury | Senior Vice President of Information Technology |
Laura Piccinini | Senior Vice President & GM of Cardiovascular and International |
Marna I. Bronfen-Moore | Senior Vice President of Human Resources |
Saleem M. Cheeks | Vice President of Communications |
Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 02, 2025 | 10-Q | Quarterly Report |
Apr 02, 2025 | 8-K | Current Report |
Apr 02, 2025 | 8-K | Current Report |
Feb 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 13, 2025 | SCHEDULE 13G | Filing |
Feb 05, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 17, 2025 | 4 | Filing |
Jan 16, 2025 | 8-K | Current Report |
Jan 08, 2025 | 10-Q | Quarterly Report |
Jan 08, 2025 | 8-K | Current Report |